CATALYSTYahoo Finance • 13h ago
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to NoteYahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
Why GILD Stock surged +3.06% Today — RQD Quant Desk Flash
$170.68 +3.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $172.03
Gilead Sciences Inc. (GILD) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (79% profit margin, 21% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE A- • BUY
Cap $205.35B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GILD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GILD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Gilead Sciences Inc. (NASDAQ: GILD) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $170.68 (+3.06% 1D, market cap $205.35B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, GILD ranks #9 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GILD compare to AMGN and MRNA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GILD carries a Roarable A- (82/100 RQD), trailing P/E of 24.1x, gross margin of 78.8%, and ROIC of 21.0%. By comparison, AMGN (Amgen Inc.) holds a B- grade (71/100 RQD, P/E 32.3x, ROIC 14.5%, cap $249.09B) and MRNA (Moderna Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -34.1%, cap $88.93B). Among the 5-stock peer group, GILD leads on earnings multiple (24.1x) while GILD leads on capital efficiency (21.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GILD?
▼
Per GILD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000882095), Gilead Sciences Inc. generated $29.44B in revenue (+2.4% YoY), $8.51B in net income, and $9.46B in free cash flow against $59.02B in total assets and $22.13B in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $172.03 (+0.79%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 32.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • A-
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw A- · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GILD)Realized 20D OHLCV Swing Band: ±5.9%
Deterministic 5-Pillar Attribution (82/100 Composite)
🔍 WHY GILD SCORES 82/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (23% of score)
20D Institutional Volume Accumulation (±5.9% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)
Altman Z-Score 5.87 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Macro Regime Fit14/20 pts (-6 pt drag)
Macro rate sensitivity & RSI-14 (64.3) create a -6 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B+$147.92+5.8% Next Q
74
Q2 (-2Q)Grade B+$156.51+1.6% Next Q
77
Q3 (-1Q)Grade A-$159.08+7.3% Next Q
79
CurrentGrade A-$170.68+8.6% Hist 90D α
82
Trajectory: B+ (74) → A- (82)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the GILD Bull Thesis Could Fail
Even with a 82/100 (A-) score, GILD faces multiple-compression risk if 24.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 76.3% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($151.64) or 200D SMA ($140.31) invalidates the momentum regime and cuts Target Base ($189.11) toward Bear Floor ($139.96).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GILD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GILD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GILD Stock surged +3.06% Today — RQD Quant Desk Flash
Gilead Sciences Inc. (GILD) surged +3.06% to $170.68, trading at 92% of its 52-week range ($116.88 – $175.65). High-quality cash engine (79% profit margin, 21% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 92% of its 52-week range ($116.88 – $175.65) with RSI-14 at 64.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.9% around $170.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable A- (Buy) backed by 78.8% gross margin and $9.5B annual free cash flow.
Live GILD Headlines & Catalysts
MARKET WIRETrefis • 16h ago
Why Is Everyone Ignoring Gilead Stock’s High Cash Yield?Trefis report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvestor's Business Daily • 19h ago
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeInvestor's Business Daily report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 22h ago
How to Buy Gilead Sciences Stock (GILD)The Motley Fool report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 1d ago
BofA raises Gilead Sciences stock price target on growth outlookInvesting.com report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Can Gilead (GILD) Stock Continue Rising in 2027?Yahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Gilead Sciences (GILD) Laps the Stock Market: Here's WhyYahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 10h ago
Gilead (GILD) Stock Fair Value Edges Higher After Analyst Target IncreasesPrice targets for Gilead Sciences have shifted higher, with the updated fair value estimate moving from US$158.65 to US$165.31. Recent Street research describes a tilt toward higher targets, as analysts weigh Q3 executio
RISK WATCHYahoo • 13h ago
Former Gilead Head of U.S. Medical Affairs Dean Hakanson, MD, Joins GOA Therapeutics as Chief Medical OfficerPhysician and biopharma executive, who led U.S. Medical Affairs for Gilead’s launch of remdesivir, brings 40 years of experience spanning clinical practice, drug development, medical affairs and the launch of new therapi
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (GILD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GILD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.63%📐 HORIZONTAL RANGE
2026-11-02O $159.2H $170.7L $159.2C $170.7VOL 8.43M
RES: $176.6SUP: $142.1SMA50: $151.6SMA200: $140.3
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GILD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
17.8%/yr Implied 5Y Growth
vs. +2.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GILD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GILD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GILD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GILD)
Health Care Rank #9 of 1016
⚔️ AMGN vs GILD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GILD vs. AMGN, MRNA, ARGX, RVMD)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Gilead Sciences Inc. (GILD) ranks #9 by composite RQD confidence (82/100, grade A-) and #10 by equity capitalization ($205.35B). Within this direct 5-issuer industry benchmark cohort, GILD leads on earnings valuation at 24.1x trailing P/E, while GILD leads on capital efficiency and profitability with 21.0% ROIC and 78.8% gross margin. GILD currently leads its immediate peer cohort in composite quantitative strength at 82/100 (A-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GILD
ACTIVE
Gilead Sciences Inc. | A- | 82/100 | 24.1x | 78.8% | 21.0% | +3.06% | $205.35B | Benchmark Subject |
| AMGN Amgen Inc. | B- | 71/100 | 32.3x | 67.2% | 14.5% | +1.15% | $249.09B | /amgn-vs-gild → |
| MRNA Moderna Inc. | C- | 60/100 | — | 55.3% | -34.1% | -0.47% | $88.93B | /mrna-vs-gild → |
| ARGX argenx SE | C | 63/100 | 32.8x | — | 9.9% | -0.56% | $55.72B | /argx-vs-gild → |
| RVMD Revolution Medicines Inc. | D+ | 55/100 | — | — | -28.6% | +0.55% | $40.78B | /rvmd-vs-gild → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000882095In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gilead Sciences Inc. (GILD) reported GAAP revenue of $29.44B (+2.4% vs. FY2024 revenue of $28.75B , and +8.6% cumulative change since FY2023) , GAAP net income of $8.51B, operating cash flow of $10.02B, and free cash flow of $9.46B (-8.2% YoY). On the balance sheet, GILD closed FY2025 with $59.02B in total assets against $22.13B in total debt (Altman Z-Score: 5.87, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $29.44B | $8.51B | $10.02B | $9.46B | $59.02B | $22.13B |
| FY2024 (FY) | 2024-12-31 | $28.75B | $480.0M | $10.83B | $10.30B | $58.99B | $24.90B |
| FY2023 (FY) | 2023-12-31 | $27.12B | $5.67B | $8.01B | $6.79B | $112.94B | $26.43B |
3. GILD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GILD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Gilead Sciences Inc. (NASDAQ: GILD) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $170.68 (+3.06% 1D, market cap $205.35B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 19/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, GILD ranks #9 in composite RQD confidence.
How does GILD compare to AMGN and MRNA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GILD carries a Roarable A- (82/100 RQD), trailing P/E of 24.1x, gross margin of 78.8%, and ROIC of 21.0%. By comparison, AMGN (Amgen Inc.) holds a B- grade (71/100 RQD, P/E 32.3x, ROIC 14.5%, cap $249.09B) and MRNA (Moderna Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -34.1%, cap $88.93B). Among the 5-stock peer group, GILD leads on earnings multiple (24.1x) while GILD leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GILD?
Per GILD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000882095), Gilead Sciences Inc. generated $29.44B in revenue (+2.4% YoY), $8.51B in net income, and $9.46B in free cash flow against $59.02B in total assets and $22.13B in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GILD trading relative to its 50-day, 200-day, and 52-week technical levels?
GILD last traded at $170.68 (+3.06% on volume of 11,427,263 shares), positioning the stock +12.56% above its 50-day simple moving average ($151.64) and +21.64% above its 200-day simple moving average ($140.31). Across its 52-week range of $116.88 to $175.65, GILD sits at the 91.5% percentile with a 14-day RSI of 64.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.9% ($160.61 to $180.75).
GILD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GILD stock moving today?
Why GILD Stock surged +3.06% Today — RQD Quant Desk Flash. High-quality cash engine (79% profit margin, 21% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 82/100 (A-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
GILD — Gilead Sciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:09:07Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, GILD scores 82 out of 100 with a letter grade of A- and a verdict label of "Roarable Buy — Superior Risk/Reward." The five pillars are:
- Fundamental Cash Engine (15 / 20): Per the RQD rating, ROIC is 21% and FCF yield is 4.6%. This pillar is solid but is the lowest-scoring of the five, indicating that cash generation relative to the valuation is a comparatively weaker leg of the thesis than other factors.
- Whale 13F Flow (19 / 20): The rating describes institutional accumulation and options positioning as a strength. This is the highest-scoring pillar. Note that the holders section of the source data is empty, so the underlying 13F detail cannot be verified in this dossier.
- Insider Conviction (16 / 20): The rating cites SEC Form 4 and Congressional PTR cluster flow as supportive. Underlying transaction records are not provided in the source data.
- Macro Regime Fit (14 / 20): Per the RQD rating, beta is 0.88 and sector sensitivity is a factor. A beta below 1.0 implies, per the rating's framing, lower sensitivity to broad market moves than the overall market.
- Forensic Balance Sheet (18 / 20): Per the RQD rating, Altman Z is 5.87, Piotroski F is 8 out of 9, and Debt/Equity is 0.97. This is the second-highest pillar and supports the view of a financially sound balance sheet.
For a prospective investor, the investment implications drawn from these pillars are as follows. The upside drivers are the institutional flow and balance-sheet strength. The valuation tradeoff is that the stock trades at a trailing P/E of 24.1 and an EV/EBITDA of 21 per the market data, which are not low absolute multiples, so the thesis leans on the quality and durability of earnings rather than on cheapness. The FCF yield of 4.6% is the pillar with the most room for scrutiny. This analysis is educational and is not personalized financial advice.
Snapshot
Business
Gilead Sciences Inc. (GILD) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company carries a market capitalization of $205.3B. Per the market data, its gross margin is 78.8%, operating margin is 34%, and net margin is 28.9%. The source data does not describe its specific products, customers, or revenue model beyond these classifications.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $29443.0M | $10022.0M | $8510.0M | N/A | $9456.0M | N/A | $22129.0M |
| FY 2024 | $28754.0M | $1662.0M | $480.0M | N/A | $10305.0M | N/A | $24896.0M |
| FY 2023 | $27116.0M | $7605.0M | $5665.0M | N/A | $6785.8M | N/A | $26428.4M |
Per the SEC financials, revenue rose across the three reported periods, from $27116.0M in FY 2023 to $29443.0M in FY 2025. Net income moved from $5665.0M to $480.0M in FY 2024 and then to $8510.0M in FY 2025, and operating income followed a similar path. Per the Roarable RQD rating, ROIC is 21%, the Altman Z-Score is 5.87, and the Piotroski F-Score is 8 out of 9. Per the same rating, Debt/Equity is 0.97, and debt was reported at $22129.0M in FY 2025, down from $26428.4M in FY 2023.
Recent Catalysts & News Wire Analysis
Per the recent news feed, five items are listed for GILD:
- A Yahoo Finance report describing a stock decline despite market gains, flagged GREEN as a CATALYST.
- A Trefis report on the company's cash yield, flagged YELLOW as MARKET WIRE.
- An Investor's Business Daily report stating the company hit a record and posted its best sales growth in a decade, flagged GREEN as a CATALYST.
- A Motley Fool buying guide, flagged YELLOW as MARKET WIRE.
- An Investing.com report that BofA raised its price target on growth outlook, flagged GREEN as a CATALYST.
- A Yahoo Finance piece on whether the stock can keep rising in 2027, flagged YELLOW as MARKET WIRE.
The green-flagged items are the catalyst-type reports and the yellow-flagged items are general market commentary. The headlines are the only content available; the underlying articles are not included in the source data. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be established from the source data.
Open Questions
- What are the company's specific products and revenue drivers, given that the source data provides only sector and industry classifications?
- Why are EPS and cash balances marked N/A across all reported periods, and how do those figures reconcile with net income and FCF?
- What explains the swing in net income from $5665.0M in FY 2023 to $480.0M in FY 2024 before recovering to $8510.0M in FY 2025?
- What are the consensus rating and price targets, given that the analyst data is empty?
- What is the identity and size of the institutional and insider holders behind the whale and insider pillar scores?
GILD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Gilead Sciences Inc. (GILD) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 13h ago
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 16h ago
Why Is Everyone Ignoring Gilead Stock’s High Cash Yield? Trefis report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investor's Business Daily • 19h ago
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade Investor's Business Daily report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 22h ago
How to Buy Gilead Sciences Stock (GILD) The Motley Fool report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 1d ago
BofA raises Gilead Sciences stock price target on growth outlook Investing.com report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Can Gilead (GILD) Stock Continue Rising in 2027? Yahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Gilead Sciences (GILD) Laps the Stock Market: Here's Why Yahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance report covering Gilead Sciences Inc. (GILD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GILD Bull vs. Bear Conversation Board — What's Your Call at $170.68?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GILD 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $195.42 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is GILD (A- • RQD 82/100) a Buy at $165.61?
Welcome to the GILD (Gilead Sciences Inc.) Roar Pit. Current RQD Composite is 82/100 (Roarable Buy — Superior Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (21.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $125.86 (-24.0%)
Spot @ $165.61 Pump the brakes on GILD — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on GILD, but look at what you are paying: 24.1x trailing P/E with 78.8% gross margins. Unless Gilead Sciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $193.76 (+17.0%)
Spot @ $165.61 GILD cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on GILD, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $165.61 (52-wk range $116.88 - $175.65), any beat on forward guidance forces shorts and underweight funds to chase.